



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket 044508-5008

Application No. 10/578,438

Applicants: Ajay Verma *et al.*

Page 1 of 2

Filing Date: May 5, 2006

Group Art Unit: Unassigned

## U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	6,222,015	04/24/2001	Wilkinson	530 350	08/25/1998

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/T.L./	2.	Albina <i>et al.</i> (2001), HIF-1 expression in healing wounds: HIF-1 $\alpha$ induction in primary inflammatory cells by TNF- $\alpha$ . <i>Am. J. Physiol. Cell Physiol.</i> 281(6): C1971-7
	3.	Anzellotti <i>et al.</i> (2000), Novel flavonol 2-oxoglutarate dependent dioxygenase: affinity purification, characterization, and kinetic properties. <i>Arch Biochem Biophys.</i> 382(2):161-72.
	4.	Bruick <i>et al.</i> (2001), A conserved family of prolyl-4-hydroxylases that modify HIF. <i>Science.</i> 294(5545):1337-40
	5.	Carbon-Ambriz <i>et al.</i> (1987), Lactate and pyruvate increase the incorporation of [3H]proline into collagen [3H]hydroxyproline in liver slices of CCl <sub>4</sub> cirrhotic rats. <i>Lab Invest.</i> 57(4):392-6.
	6.	Chang <i>et al.</i> (2003), Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes. <i>Diabetologia.</i> 46(9):1220-7.
	7.	Cramer <i>et al.</i> (2003), A novel role for the hypoxia inducible transcription factor HIF-1 $\alpha$ : critical regulation of inflammatory cell function. <i>Cell Cycle.</i> 2(3):192-3.
	8.	Fink (2003) Ethyl pyruvate: a novel anti-inflammatory agent. <i>Crit Care Med.</i> 31(1 Suppl):S51-6
	9.	Hanauske-Abel <i>et al.</i> (2003), The HAG mechanism: a molecular rationale for the therapeutic application of iron chelators in human diseases involving the 2-oxoacid utilizing dioxygenases. <i>Curr Med Chem.</i> 10(12):1005-19
	10.	Hawaleshka <i>et al.</i> (1998), Ischaemic preconditioning: mechanisms and potential clinical applications <i>Can J Anaesth.</i> 45(7):670-82.
	11.	Ivan <i>et al.</i> (2002), Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. <i>Proc Natl Acad Sci U S A.</i> 99(21):13459-6
	12.	Jensen <i>et al.</i> (1986), Effect of lactate, pyruvate, and pH on secretion of angiogenesis and mitogenesis factors by macrophages. <i>Lab Invest.</i> 54(5): 574-8
	13.	Jones <i>et al.</i> (2001), Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. <i>J Cereb Blood Flow Metab.</i> 21(9):1105-14
	14.	Kaule <i>et al.</i> (1998), Prolyl hydroxylase activity in tissue homogenates of annelids from deep sea hydrothermal vents. <i>Matrix Biol.</i> 17(3):205-12.
	15.	Knowles <i>et al.</i> (2003), Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. <i>Cancer Res.</i> 63(8):1764-8.
	16.	Koritzinsky <i>et al.</i> (2001), Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. <i>Int. J. Radiat. Biol.</i> 77(3): 319-328.
	17.	Lee <i>et al.</i> (2001), Angiogenic activity of pyruvic acid in vivo and in vitro angiogenesis models. <i>Cancer Res.</i> 61(8):3290-3.
	18.	Lu <i>et al.</i> (2002), Hypoxia-inducible Factor-1 Activation by Glycolysis Implicates the Warburg Effect in Carcinogenesis. <i>J. Biol. Chem.</i> 277: 23111-23115.
/T.L./	19.	Ng. <i>et al.</i> (1991), Cosubstrate Binding Site of Pseudomonas sp. AK1 $\alpha$ -Butyrobetaine Hydroxylase. <i>J. Biol. Chem</i> 266(3): 1526-1533.

Examiner

/Trevor Love/

Date Considered

01/05/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary) PTO Form 1449		Attorney Docket 044508-5008	Application No. 10/578,438
		Applicants: <b>Ajay Verma <i>et al.</i></b>	Page 2 of 2
		Filing Date: May 5, 2006	Group Art Unit: Unassigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>			
/T.L./	20.	Ruscher <i>et al.</i> (2002), Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. <i>J Neurosci.</i> 22(23):10291-301.	
	21.	Sawyer (1995), Practical applications of neuronal tissue culture in in vitro toxicology. <i>Clin Exp Pharmacol Physiol.</i> 22(4):295-6.	
	22.	Scheid <i>et al.</i> (2000), Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair. <i>Pediatr Surg Int.</i> 16(4): 232-6	
	23.	Semenza G.L. (2001), Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. <i>Trends Mol Med.</i> 7(8):345-50.	
↓ /T.L./	24.	Warnecke <i>et al.</i> (2003), Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. <i>FASEB J.</i> 17(9):1186-8.	
Examiner /Trevor Love/		Date Considered 01/05/2009	
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			